Topical Ivermectin-Antibiotic Compositions for Demodex Blepharitis

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current treatments for demodex-related blepharitis, such as tea tree oil and oral ivermectin, often cause eye irritation and fail to effectively eradicate demodex mites and associated bacteria, leading to persistent symptoms.

Innovation Solution

A topical pharmaceutical composition combining ivermectin and an antibiotic, such as oxytetracycline, formulated in a non-irritating cream or ointment, is applied directly to the eyelids to kill demodex mites and bacteria, avoiding systemic side effects and ensuring adequate concentration at the target site.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If tea tree oil is used to treat demodex infestations, then demodex mites are killed, but eye irritation and stinging sensations occur

Engineering Contradiction:
Improveefficacy against demodexVSAvoideye irritation
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent combines ivermectin (a parasiticide effective against demodex) with an antibiotic agent (to treat associated bacteria) and a corticosteroid (to reduce inflammation). This combination therapy addresses multiple aspects of the condition simultaneously while using agents with more favorable safety profiles than tea tree oil, thereby maintaining efficacy while reducing ocular irritation.

Inventive Principle:
Principle #5Merging (Combining)

Solution Approach 2:

The invention creates a composite pharmaceutical composition containing multiple active ingredients (ivermectin, antibiotic, and corticosteroid) in specific concentrations. This composite formulation leverages the synergistic effects of different agents to achieve reliable demodex eradication while minimizing harmful side effects through the anti-inflammatory and protective properties of the corticosteroid component.

Inventive Principle:
Principle #40Composite materials

2Reliability

If oral ivermectin is administered to treat demodex, then demodex mites are killed, but the treatment is expensive and requires repeated dosing

Engineering Contradiction:
Improveefficacy against demodexVSAvoidtreatment duration
Core Design Contradiction:
ReliabilityVSLoss of time

Solution Approach 1:

The patent applies ivermectin topically directly to the affected eyelid margins and lash follicles before demodex infestation becomes severe. This preliminary and direct application ensures high local concentrations of the parasiticide at the target site, achieving effective eradication in a single application rather than requiring multiple oral doses over time.

Inventive Principle:
Principle #10Preliminary action

Solution Approach 2:

The invention extracts ivermectin from its systemic oral administration route and delivers it directly to the local site of infestation through topical application. This extraction of the active ingredient from systemic therapy and its targeted delivery to the eyelid margins eliminates the need for repeated dosing and reduces overall treatment time while maintaining efficacy.

Inventive Principle:
Principle #2Taking out (Extraction)

3Ease of operation

If diluted shampoo is used for eyelid margin scrub, then some demodex control is achieved, but the treatment frequently fails to eradicate the parasite

Engineering Contradiction:
Improveease of applicationVSAvoidefficacy against demodex
Core Design Contradiction:
Ease of operationVSReliability

Solution Approach 1:

The patent changes the concentration parameter of the active ingredient by formulating ivermectin at optimized concentrations (0.1-10 mg/mL) in the topical composition, which is significantly higher and more precisely controlled than diluted shampoo. This parameter optimization ensures reliable demodex eradication while maintaining ease of topical application similar to shampoo-based treatments.

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The invention creates a composite formulation that combines ivermectin with antibiotic and corticosteroid agents, providing a multi-functional product that not only addresses demodex infestation but also treats associated bacterial infections and inflammation. This composite approach ensures comprehensive treatment and eradication of the parasite and its complications in a single easy-to-apply topical product.

Inventive Principle:
Principle #40Composite materials

4Reliability

If high concentration ivermectin is applied topically, then demodex mites are killed, but the composition may cause irritation

Engineering Contradiction:
Improveefficacy against demodexVSAvoidocular surface irritation
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent introduces a corticosteroid agent as an intermediary substance in the topical composition that mediates between the high concentration ivermectin (which could be irritating) and the ocular surface. The corticosteroid reduces inflammation and irritation caused by the parasiticide, allowing high concentrations of ivermectin to be used effectively while protecting the ocular surface from harmful effects.

Inventive Principle:
Principle #24Intermediary (Mediator)

Data Source

PatentUS20250213602A1Pharmaceutical compositions for demodex related blepharitis and eyelid crusting
Publication Date: 2025.07.03 TARSUS PHARMACEUTICALS INC

AI summary

Formulation of ectoparasiticidal and antibiotic “compositions into pharmaceutical compositions useful for the treatment of eyelid inflammation, in particular demodex related blepharitis and eye crusting.